InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,167.60
(
0.00%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.33
(
0.24%
)
Bitcoin
66,079.52
(
-0.84%
)
Post# of 647234
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

BioSpecialist

Send PM Follow Ignore
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

BioSpecialist

Re: None

Tuesday, 02/18/2020 1:56:55 PM

Tuesday, February 18, 2020 1:56:55 PM

Post# of 647234
XERS =MC $140 M - Cash $130 M -- FDA approved treatment for severe hypoglycemia will be launched next Q --3x Phase 2 readouts for different indications during 1H 2020 /Brutally underpriced and undiscovered stock with HUGE upside


https://www.fiercepharma.com/pharma/xeris-scores-first-fda-nod-shelf-stable-glucagon-injector

RBC Capital Markets analyst Randall Stanicky said the wait on the autoinjector was only a "modest surprise" and projected peak sales for Gvoke at $248 million per year in 2024.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up